Items where Author is "Melichar, Bohuslav"

Article

Rini, Brian I. and Plimack, Elizabeth R. and Stus, Viktor and Waddell, Tom and Gafanov, Rustem and Pouliot, Frédéric and Nosov, Dmitry and Melichar, Bohuslav and Soulieres, Denis and Borchiellini, Delphine and Vynnychenko, Ihor O. and McDermott, Raymond S. and Azevedo, Sergio Jobim and Tamada, Satoshi and Kryzhanivska, Anna and Li, Chenxiang and Burgents, Joseph E. and Molife, L. Rhoda and Bedke, Jens and Powles, Thomas (2021) Pembrolizumab (pembro) plus axitinib (axi) versus sunitinib as first-line therapy for advanced clear cell renal cell carcinoma (ccRCC): Results from 42-month follow-up of KEYNOTE-426. Journal of Clinical Oncology, 39 (15 s.1). p. 4500. ISSN 0732-183X (Print); 1527-7755 (Electronic); 0732-183X (Linking)

Plimack, Elizabeth R. and Rini, Brian I. and Stus, Viktor and Gafanov, Rustem and Waddell, Tom and Nosov, Dmitry and Pouliot, Frédéric and Soulieres, Denis and Melichar, Bohuslav and Vynnychenko, Ihor and Azevedo, Sergio Jobim and Borchiellini, Delphine and McDermott, Raymond S. and Bedke, Jens and Tamada, Satoshi and Yin, Lina and Chen, Mei and Molife, L. Rhoda and Atkins, Michael B. and Powles, Thomas (2020) Pembrolizumab plus axitinib versus sunitinib as first-line therapy for advanced renal cell carcinoma (RCC): Updated analysis of KEYNOTE-426. Journal of Clinical Oncology, Vol.38 (15supp). p. 5001. ISSN 1527-7755 (online, version of record) and 0732-183X (print)

Powles, Thomas and Plimack, Elizabeth R. and Soulieres, Denis and Waddell, Tom and Stus, Viktor and Gafanov, Rustem and Nosov, Dmitry and Pouliot, Frédéric and Melichar, Bohuslav and Vynnychenko, Ihor and Azevedo, Sergio J and Borchiellini, Delphine and McDermott, Raymond S and Bedke, Jens and Tamada, Satoshi and Yin, Lina and Chen, Mei and Molife, L Rhoda and Atkins, Michael B and Rini, Brian I (2020) Pembrolizumab plus axitinib versus sunitinib monotherapy as first-line treatment of advanced renal cell carcinoma (KEYNOTE-426): extended follow-up from a randomised, open-label, phase 3 trial. The Lancet Oncology, 21 (No. 12). pp. 1563-73. ISSN 1470-2045

Al-Batran, Salah-Eddin and Schuler, Martin H. and Zvirbule, Zanete and Manikhas, Georgiy and Lordick, Florian and Rusyn, Andriy and Vynnyk, Yuriy and Vynnychenko, Ihor and Fadeeva, Natalia and Nechaeva, Marina and Dudov, Assen and Gotovkin, Evgeny and Pecheniy, Alexander and Bazin, Igor and Bondarenko, Igor and Melichar, Bohuslav and Mueller, Christian and Huber, Christoph and Tureci, Oezlem and Sahin, Ugur (2016) FAST: An international, multicenter, randomized, phase II trial of epirubicin, oxaliplatin, and capecitabine (EOX) with or without IMAB362, a first-in-class anti-CLDN18.2 antibody, as first-line therapy in patients with advanced CLDN18.2+ gastric and gastroesophageal junction (GEJ) adenocarcinoma. Journal of Clinical Oncology, Vol 34 (No18_s). P.-LBA4001. ISSN 0732-183X (Print) ; 1527-7755 (Electronic) ; 0732-183X (Linking)